- Home
- Industries
Aerospace And Defence
Agriculture
Automotive And Transportation
Banking And Finance
Business
Chemicals And Materials
Consumer And Retail
Electronics And Semiconductors
Food And Beverages
Machinery & Equipments
Manufacturing And Construction
Medical Devices
Others
Pharmaceuticals And Healthcare
Power And Energy
Sports
Technology
- Services
- News Room
- About us
- Contact Us
-
Global Exosome Therapeutics Market Size, Share & Forecast | CAGR of 10.3%
Global Exosome Therapeutics Market Size, Share, Growth By Therapeutic Application (Oncology, Neurology, Cardiovascular, Regenerative Medicine), By Source (MSC-Derived, Immune, Dendritic Cell), By Technology (Isolation, Purification, Engineering, Drug Delivery) Region, Key Players – Dynamics, Extracellular Vesicles & Advanced Biologics Platform Trends & Forecast 2026-2034
Report Overview
| Market Size (2025) | Forecast Value (2034) | CAGR (2026–2034) | Largest Region (2025) |
| USD 1.39 Billion | USD 3.36 Billion | 10.3% | North America, 46.8% |
The Exosome Therapeutics Market was valued at approximately USD 1.26 billion in 2024 and reached USD 1.39 billion in 2025. The market is projected to grow to USD 3.36 billion by 2034, expanding at a CAGR of 10.3% during the forecast period from 2026 to 2034. This represents an absolute dollar opportunity of USD 1.97 billion over the analysis period, as exosomes—nano-sized extracellular vesicles measuring 30–150 nanometers secreted by virtually all cell types—transition from exclusively research tools into a clinically validated therapeutic modality spanning oncology, neurology, regenerative medicine, and rare genetic diseases.
Exosome Therapeutics Market Global Forecast to 2034 (USD)
CAGR OF
10.3%
Exosome Therapeutics Market
Get more details on this report -
Exosomes carry bioactive cargo including proteins, lipids, messenger RNA, microRNA, and DNA, enabling cell-to-cell communication across biological barriers that conventional drug delivery systems cannot reliably cross. Their capacity to traverse the blood-brain barrier (BBB) naturally—without the immunogenicity associated with viral vectors or the potency limitations of lipid nanoparticles (LNPs)—positions exosome-based delivery as a structurally differentiated platform for CNS therapeutics, which represent the largest unmet delivery challenge in modern pharmacology. The field crossed a landmark regulatory threshold when Capricor Therapeutics, Inc. filed the sector's first Biologics License Application (BLA) on January 2, 2025, for deramiocel (CAP-1002), its cardiosphere-derived cell therapy whose mechanism of action is exosome-mediated. The FDA assigned a Priority Review designation with an original PDUFA action date of August 31, 2025; following a Complete Response Letter (CRL) in July 2025 and subsequent resubmission supported by HOPE-3 trial data, the FDA accepted the application as a Class 2 resubmission with a new PDUFA date of August 22, 2026.
Manufacturing scalability and GMP compliance define the current bottleneck separating laboratory promise from commercial reality. As of 2025, Lonza Group AG has emerged as the sector's dominant contract development and manufacturing organization (CDMO) for exosome therapeutics, entering separate GMP manufacturing collaborations with RION in September 2025 for platelet-derived Purified Exosome Product (PEP) and with Exogenus Therapeutics in March 2025 for Exo-101—two transactions that collectively signal the beginning of industrialization for this modality. Approximately 81 clinical trials involving exosome-based therapeutics were actively recruiting as of 2025, a 4-fold increase from 2020 levels that forces upstream suppliers to develop standardized isolation, characterization, and storage solutions at industrial throughput.
Regulatory frameworks for exosome therapeutics are consolidating under the U.S. Public Health Service Act Section 351, which classifies exosome biologics requiring rigorous licensure equivalent to biologics license applications. The FDA's Center for Biologics Evaluation and Research (CBER) oversees this pathway, and the agency's issuance of an Investigational New Drug (IND) clearance to Aruna Bio, Inc. in January 2024 and its Priority Review designation for Capricor's BLA collectively demonstrate that a functional regulatory pathway exists for companies meeting Good Manufacturing Practice and clinical evidence standards. The sector is structurally bifurcated between companies developing “naïve” exosomes—those leveraging innate biological properties of naturally secreted vesicles—and companies engineering exosomes with therapeutic cargo payloads of RNA, proteins, gene-editing tools, or small molecules.
North America held the largest regional share at 46.8% in 2025, valued at approximately USD 651 million, anchored by the U.S. biotechnology ecosystem, NIH funding for extracellular vesicle research, and Capricor's regulatory milestone. Asia Pacific is the fastest-growing region, driven by increasing cancer incidence, government biotechnology investment programs in China, South Korea, and Japan, and the operational presence of ILIAS Biologics (South Korea) and ExoCoBio (South Korea) among the sector's most technically advanced engineered exosome developers. Europe contributes approximately 25% of market revenue, led by Belgium's EXO Biologics, Portugal's Exogenus Therapeutics, and UK-based Evox Therapeutics.
Market Definition & Scope
The exosome therapeutics market is defined as the commercial and clinical-stage market for therapeutic applications of exosomes and related extracellular vesicles (EVs) as active pharmaceutical ingredients, drug delivery vehicles, or immunomodulatory agents in the treatment or prevention of human diseases. The market encompasses naïve exosomes (naturally secreted vesicles leveraged for their intrinsic regenerative, anti-inflammatory, and immunomodulatory properties), engineered exosomes (vesicles modified to carry defined therapeutic payloads including antisense oligonucleotides, siRNA, mRNA, CRISPR-Cas9 complexes, proteins, and small molecules), and exosome-derived products such as lyophilized platelet-derived preparations. The delivery formats include intravenous infusion systems, topical formulations, inhaled aerosols, and intrathecal injection preparations. Upstream enabling technologies covered include exosome isolation methods (ultracentrifugation, size exclusion chromatography, precipitation-based methods, microfluidics-based isolation, immunoaffinity capture), characterization platforms (nanoparticle tracking analysis, flow cytometry, transmission electron microscopy), and cargo loading systems (sonication, electroporation, incubation-based passive loading).
This analysis covers exosome therapeutics in active clinical development (Phase I through Phase III), those in pre-BLA regulatory submissions or under FDA/EMA review, and commercial-stage products where approved. Explicitly excluded are pure exosome diagnostics platforms (liquid biopsy tests, biomarker assays), research-use-only (RUO) kits and reagents not intended for therapeutic application, cosmetic exosome formulations, and veterinary exosome applications, each of which constitutes a distinct adjacent segment. The exosome therapeutics market is a sub-segment of the broader extracellular vesicle therapeutics category, which itself sits within the advanced therapy medicinal products (ATMPs) and biologics landscape. The total exosome market including diagnostics, research tools, and therapeutics was valued at approximately USD 222–241 million in 2025, with the therapeutics segment representing the highest projected growth trajectory.
Key Takeaways
- Market Growth: The global exosome therapeutics market advanced from approximately USD 0.89 billion in 2020 to USD 1.39 billion in 2025 and is forecast to reach USD 3.36 billion by 2034, a 10.3% CAGR over the 2025–2034 period, generating an absolute dollar opportunity of USD 1.97 billion as the sector transitions from primarily pre-commercial to commercial status.
- Segment Dominance (Application): Oncology held the largest therapeutic application share at 40.0% in 2024, valued at approximately USD 556 million, driven by exosomes' demonstrated capacity to deliver targeted anti-tumor payloads to solid tumors while modulating tumor-associated macrophage polarization—a dual mechanism unavailable to conventional chemotherapy or antibody-drug conjugates.
- Segment Dominance (Source): Mesenchymal stem cell (MSC)-derived exosomes commanded a 45.0% share of the exosome therapeutics market by exosome source in 2024, reflecting MSCs' well-characterized regenerative and immunomodulatory secretome, established GMP culture protocols, and the largest body of clinical safety data of any exosome cell source.
- Driver: The structural inability of conventional drug delivery systems—including lipid nanoparticles, viral vectors, and antibody-drug conjugates—to cross the blood-brain barrier efficiently is the primary commercial pull for neural exosome therapeutics, enabling companies such as Aruna Bio (ABEx platform) and Evox Therapeutics (DeliverEX platform) to access CNS indications currently unreachable by competing modalities.
- Restraint: GMP-compliant exosome manufacturing at commercial scale remains the sector's defining technical and commercial barrier; yield variability between production batches, the absence of universally accepted characterization standards, and the capital intensity of Good Manufacturing Practice facilities impose disproportionate cost burdens on clinical-stage biotechs relative to their cash reserves.
- Opportunity: The CDMO ecosystem is actively industrializing exosome manufacturing, with Lonza's separate September 2025 RION collaboration and March 2025 Exogenus collaboration signaling the beginning of third-party exosome manufacturing capacity build-out—a structural prerequisite for the sector's commercial phase that is expected to reduce per-dose production costs by 40–60% through process optimization by 2030.
- Trend: The sector is bifurcating between naïve exosome developers (RION, Capricor, Direct Biologics, Aegle Therapeutics) leveraging intrinsic vesicle biology and engineered exosome developers (Evox Therapeutics, ILIAS Biologics, Carmine Therapeutics, Aruna Bio payload programs) loading defined therapeutic cargo—a strategic choice with different scalability profiles, regulatory pathways, and competitive moat characteristics.
- Regional: North America held a 46.8% share in 2025 at approximately USD 651 million, anchored by Capricor's first-in-sector BLA filing on January 2, 2025, Capricor's USD 152 million cash position, and NIH's ongoing funding of extracellular vesicle research programs across approximately 45 U.S.-based academic institutions.
Key Insights Summary
- Capricor Therapeutics filed the sector's first BLA on January 2, 2025, for deramiocel (CAP-1002), an allogeneic cardiosphere-derived cell therapy for DMD cardiomyopathy whose therapeutic mechanism is exosome-mediated macrophage reprogramming; the FDA accepted the BLA with Priority Review and an original PDUFA date of August 31, 2025. After the FDA issued a Complete Response Letter in July 2025, Capricor resubmitted supported by HOPE-3 trial data; the FDA accepted the resubmission as Class 2 with a new PDUFA action date of August 22, 2026, at which time no potential review issues were identified.
- On September 23, 2025, RION formalized a collaboration with Lonza for cGMP commercial-scale manufacturing of its Purified Exosome Product (PEP)—a platelet-derived, lyophilized exosome formulation with immunomodulatory and tissue regenerative properties—at Lonza's Houston, Texas facility, the first major CDMO-scale exosome manufacturing agreement for a multi-indication regenerative medicine pipeline covering wound care, dermatology, musculoskeletal disease, pulmonary disease, and cardiovascular health.
- On March 11, 2025, Exogenus Therapeutics engaged Lonza's Siena, Italy site to develop a GMP-compliant manufacturing process for Exo-101—derived from immunologically privileged umbilical cord blood cells with a multifactorial anti-inflammatory and regenerative mechanism of action—with first-in-human studies planned for 2027, representing the second consecutive Lonza exosome manufacturing partnership within a twelve-month window.
- In April 2024, EXO Biologics secured EUR 16 million in Series A funding to advance EXOB-001, the first EMA-authorized clinical trial of MSC-based exosomes, in the EVENEW Phase I/II study targeting bronchopulmonary dysplasia (BPD) prevention in preterm newborns; Phase I data are expected in 2025 and positive results could support an EMA conditional marketing approval application in 2028, which would represent the first European exosome drug approval.
- In July 2024, Aruna Bio received U.S. Patent No. 11,993,787 covering the composition of matter for neural exosomes derived from human neural stem cells for CNS therapeutic delivery, with exclusivity extending through 2038; the company's lead candidate AB126—advancing in IND-stage development for acute ischemic stroke—demonstrated preclinical BBB crossing and concentration in cerebellum and basal ganglia, areas where LNPs and viral vectors have historically failed to reach therapeutically meaningful concentrations.
- As of 2025, approximately 81 clinical trials involving exosome-based therapeutics are actively recruiting globally across oncology, neurology, cardiovascular, respiratory, and regenerative medicine indications—a figure that has grown from fewer than 20 in 2018—placing growing throughput demands on upstream isolation, characterization, and manufacturing infrastructure that is only now being addressed by CDMOs including Lonza and AGC Biologics.
Competitive Landscape Overview
The exosome therapeutics market is highly fragmented, with no approved exosome-only therapeutic product as of May 2026, and competitive leadership determined primarily by clinical-stage advancement, platform technology differentiation, manufacturing capability, and capital positioning rather than commercial revenue share. Capricor Therapeutics holds the most advanced regulatory position by virtue of its resubmitted BLA under review at the FDA, supported by USD 152 million in cash and a commercialization and distribution agreement with Nippon Shinyaku Co., Ltd. for the U.S. and Japan markets. RION holds the most advanced manufacturing infrastructure position, having secured cGMP commercial-scale CDMO partnership with Lonza before reaching late-phase clinical status—a sequencing that reflects management's recognition that manufacturing readiness is the longer lead-time constraint in exosome commercialization.
Two strategic archetypes define the competitive landscape. Naïve exosome developers—including RION, Capricor, Direct Biologics, and Aegle Therapeutics—leverage the innate biological properties of vesicles secreted by specific cell types (platelets, cardiosphere-derived cells, bone marrow MSCs, keratinocyte-derived MSCs), often formulated without additional cargo loading. Their competitive differentiation rests on cell source selection, GMP scalability, and the breadth and depth of clinical evidence for the native vesicle's therapeutic properties. Engineered exosome developers—including Evox Therapeutics, ILIAS Biologics (South Korea), Carmine Therapeutics, and the cargo-loading programs at Aruna Bio—seek to load defined therapeutic molecules into exosomes using proprietary display and loading technologies, aiming to combine the delivery advantages of exosomes with precise pharmacology of small molecules, oligonucleotides, or proteins. Evox's acquisition of Codiak BioSciences' platform assets for USD 2.1 million following Codiak's 2023 bankruptcy represents the sector's first significant consolidation event and Evox's recognition that the engEx scaffold technology was worth acquiring at distressed-asset pricing to accelerate its own DeliverEX program.
Competitive Landscape Matrix
| Company | HQ | Position | Key Product / Platform | Geo Strength | Recent Strategic Move |
| Capricor Therapeutics, Inc. | USA | Leader | Deramiocel (CAP-1002) — cardiosphere-derived cell/exosome therapy for DMD cardiomyopathy | N. America, Japan (Nippon Shinyaku distribution) | BLA filed Jan 2025, FDA issued CRL July 2025, resubmission accepted March 2026 with PDUFA August 22, 2026 |
| RION, Inc. | USA (Rochester, MN) | Leader | PEP™ (Purified Exosome Product) — platelet-derived lyophilized exosome platform | N. America | Partnered with Lonza for cGMP commercial-scale PEP manufacturing at Houston facility, September 23, 2025 |
| Evox Therapeutics Ltd. | UK (Oxford) | Challenger | DeliverEX™ engineered exosome platform; programs in ALS and SCA2 (spinocerebellar ataxia) | Europe, N. America | Acquired Codiak BioSciences platform assets for USD 2.1 million; advancing wholly owned neurology pipeline |
| EXO Biologics SA | Belgium | Challenger | EXOB-001 (MSC-derived exosomes for BPD in preterm infants); ExoXpert CDMO; ExoPulse platform | Europe | EUR 16 million Series A secured April 2024; EVENEW Phase I/II trial — first EMA-authorized MSC-exosome study |
| Exogenus Therapeutics | Portugal | Challenger | Exo-101 — umbilical cord blood MSC-derived exosome for tissue regeneration and inflammation | Europe | Contracted Lonza's Siena, Italy site to develop GMP-compliant Exo-101 manufacturing process, March 11, 2025 |
| Aruna Bio, Inc. | USA (Atlanta, GA) | Challenger | AB126 — neural stem cell-derived exosome (ABEx™ platform) for acute ischemic stroke and CNS conditions | N. America | US Patent No. 11,993,787 issued July 16, 2024 for neural exosome composition of matter; IND filed for AB126 |
| Direct Biologics, LLC | USA | Niche Player | ExoFlo™ — bone marrow MSC-derived EV product for ARDS and inflammatory conditions | N. America | Phase III trial ongoing for ARDS; multiple FDA-approved INDs across COVID-19 indication spectrum |
| Aegle Therapeutics Corp. | USA | Niche Player | AGLE-102 — MSC-derived EV composite for second-degree burns and epidermolysis bullosa | N. America | Positive 12-week Phase I/IIa data reported January 2024; Phase I/IIa trial for epidermolysis bullosa initiated |
By Therapeutic Application
Oncology held a 40.0% share of the exosome therapeutics market in 2024 at approximately USD 556 million, representing the largest single therapeutic application because cancer creates the clearest demand case for targeted drug delivery: chemotherapy agents kill both cancerous and healthy cells, while exosomes offer the prospect of tumor-selective delivery through surface ligand engineering and the exploitation of tumor cells' naturally elevated exosome uptake activity. The two primary oncology mechanisms under clinical investigation are exosome-mediated targeted drug delivery (loading exosomes with small molecule cytotoxics, siRNA, or immune checkpoint molecules for tumor-directed delivery) and cancer immunotherapy (using tumor-derived exosomes or dendritic cell-derived exosomes to stimulate anti-tumor immune responses). Codiak BioSciences' exoSTING candidate, which delivered a STING agonist payload engineered within exosomes to activate innate immunity within the tumor microenvironment, pioneered the engineered oncology exosome approach before the company's assets were acquired by Evox Therapeutics in 2023 following Codiak's bankruptcy. The oncology pipeline across all clinical stages encompasses approximately 32 programs as of 2025, with the highest concentration in non-small cell lung cancer, hepatocellular carcinoma, and pancreatic cancer—all tumors where conventional drug penetration is severely limited.
Neurology is the fastest-growing therapeutic application segment, projected to advance at the highest CAGR among all therapeutic areas through 2034, because the blood-brain barrier represents an unresolved delivery problem for the majority of promising CNS drug candidates and exosomes represent the most physiologically native solution to BBB penetration identified to date. Neural stem cell-derived exosomes, as developed by Aruna Bio under the ABEx platform, inherit surface proteins from neural cells that enable active transport across the BBB through mechanisms including clathrin-mediated endocytosis and membrane fusion—a property that cannot be replicated by synthetic LNPs or adeno-associated viral vectors without significant engineering effort. Aruna Bio's AB126 candidate for acute ischemic stroke, Evox Therapeutics' wholly-owned programs in ALS and spinocerebellar ataxia type 2 (SCA2), and Coya Therapeutics' COYA 302 program (launching the ALSTARS Phase 2 trial for ALS in September 2025) collectively represent the sector's most consequential near-term neurological development events. Cardiovascular disease, regenerative medicine, and infectious diseases each represent smaller but structurally growing sub-segments, with RION's PEP platform advancing across pulmonary, musculoskeletal, and cardiovascular programs from a single manufacturing infrastructure.
By Exosome Source
Mesenchymal stem cell (MSC)-derived exosomes commanded a 45.0% revenue share in 2024, reflecting the combination of MSC biology's established scientific credibility, the availability of validated GMP cell banking protocols across bone marrow, umbilical cord, and adipose tissue sources, and the largest clinical evidence base of any exosome cell type. MSC-derived exosomes carry a regenerative secretome including growth factors, anti-inflammatory cytokines, and tissue-protective microRNAs that have demonstrated consistent pre-clinical efficacy across wound healing, organ fibrosis, respiratory distress, and neuroinflammation models. Direct Biologics' ExoFlo (bone marrow MSC-derived), EXO Biologics' EXOB-001 (MSC-based), and Exogenus Therapeutics' Exo-101 (umbilical cord blood MSC-derived) all leverage MSC biology, each differentiating through specific cell source selection, cargo composition, formulation approach, and target indication. The umbilical cord MSC sub-segment is growing fastest within this category because umbilical cord-derived MSCs are immunologically privileged, available as biological waste from healthy term deliveries, and capable of higher expansion rates than adult bone marrow MSCs, reducing the cost of cell banking and exosome production.
Dendritic cell-derived exosomes represent the second-largest source segment, primarily in oncology applications where dendritic cells—the master antigen-presenting cells of the adaptive immune system—generate exosomes that carry tumor antigens, MHC-peptide complexes, and co-stimulatory molecules capable of priming cytotoxic T-cell responses against cancer. The South Korean company ILIAS Biologics uses its EXPLOR platform to engineer exosomes by loading therapeutic proteins into cells before exosome biogenesis, a strategy that can be applied across cell types including dendritic cells for immune-oncology applications. Platelet-derived exosomes, led by RION's PEP platform, represent an emerging source category with the manufacturing advantage that human platelet-rich plasma is available in large quantities from blood banks without the cell expansion steps required for MSC or dendritic cell sources—reducing the cost and time of exosome production by approximately 60% relative to MSC manufacturing. Neural stem cell-derived exosomes constitute a specialized niche led exclusively by Aruna Bio, whose ABEx platform exploits the CNS-homing properties of neural stem cell vesicles.
By Technology
Ultracentrifugation held the dominant share among isolation technologies, accounting for approximately 50% of exosome isolation workflows in clinical and research settings in 2024, because it remains the gold-standard reference method for producing high-purity exosome preparations that are acceptable to regulatory agencies including the FDA and EMA for clinical supply. The method involves sequential differential centrifugation steps that pellet exosomes at 100,000×g following removal of cells and larger debris, producing preparations with minimal protein co-isolation when combined with a density gradient purification step. The primary limitation is throughput: ultracentrifugation is inherently a batch process limited by rotor capacity, requiring multiple runs for clinical-scale production volumes and imposing yield losses at each centrifugation step that aggregate to significant per-unit cost. GMP-compliant ultracentrifugation processes are now operated by Lonza at both its Houston and Siena sites for the RION and Exogenus programs respectively.
Size exclusion chromatography (SEC) and tangential flow filtration (TFF) are growing rapidly as scalable alternatives to ultracentrifugation, increasingly adopted in the GMP manufacturing environment because they are compatible with continuous bioprocessing workflows, achieve higher throughput, and produce exosome preparations with lower protein contamination than differential centrifugation alone. Evox Therapeutics' 2023 patent (US11,640,272) specifically covers downstream purification via ultrafiltration and size-based separation steps, reflecting the company's strategic recognition that manufacturing IP is as commercially critical as therapeutic IP in the exosome field. Microfluidics-based isolation represents the fastest-growing technological segment, advancing at a projected CAGR exceeding 20% through 2034, because microfluidic devices can achieve exosome capture in less than one hour using antibody-functionalized channels or acoustic separation, enabling point-of-care and decentralized manufacturing applications that conventional ultracentrifugation cannot support. Immunoaffinity capture using antibodies against exosomal surface markers (CD63, CD9, CD81) provides the highest purity but is cost-prohibitive at clinical scale, remaining primarily a research and quality-control characterization method.
Regional Analysis
North America held the largest regional share of the exosome therapeutics market in 2025 at 46.8%, generating approximately USD 651 million, anchored by the United States as the dominant single-country market. The U.S. ecosystem supports exosome therapeutics development through NIH funding—approximately 45 U.S.-based academic institutions receiving NIH support for extracellular vesicle research programs—venture capital activity, and a regulatory pathway through FDA CBER that has actively engaged with exosome IND applications. Capricor Therapeutics' first-ever exosome-related BLA filing on January 2, 2025, validated the FDA pathway for the sector and catalyzed increased investor confidence: the company maintained a USD 152 million cash position entering 2025, supplemented by a USD 52.2 million common stock raise in late 2024. The U.S. also hosts Direct Biologics (Texas), Aruna Bio (Georgia), RION (Minnesota), and a growing cluster of academic spinouts applying for exosome-related INDs across regenerative medicine and oncology indications. North America is projected to grow at approximately 9.8% CAGR through 2034.
Europe contributed approximately 25.0% of market revenue in 2025 at approximately USD 348 million, with Belgium, the United Kingdom, Portugal, and Sweden as the primary national markets. EXO Biologics in Belgium pioneered the first EMA-authorized clinical trial involving MSC-based exosomes with EVENEW (NCT06279741), a landmark regulatory precedent for European exosome therapeutics that EMA oversight has actively supported through its ATMP framework. The UK's Evox Therapeutics, headquartered in Oxford, is the most technically advanced European exosome company in terms of engineering platform depth and pipeline breadth, having secured Codiak BioSciences' proprietary assets and advanced wholly-owned programs in ALS and SCA2 using the DeliverEX platform. The European Medicines Agency's ATMP classification pathway governs exosome therapeutics as either gene therapy medicinal products (GTMPs) or somatic cell therapy medicinal products (sCTMPs) depending on their modification status, a classification that can be advantageous for small companies through ATMP certification programs offering reduced fees and parallel scientific advice.
Asia Pacific generated approximately 20.0% of market revenue in 2025 at approximately USD 278 million and is the fastest-growing regional market, driven by South Korea's position as a leading country for exosome engineering R&D, Japan's mature biologic regulatory framework under the PMDA, and China's aggressive investment in biotechnology infrastructure. South Korea hosts ILIAS Biologics, which uses the EXPLOR intracellular protein delivery platform and has dosed clinical trial participants with ILB-202 (an engineered exosome carrying the anti-inflammatory super-repressor IκB protein), and ExoCoBio, which has raised over USD 56 million in cumulative funding to develop engineered exosomes for atopic dermatitis and other skin conditions. Japan's regulatory pathway under the Act on the Safety of Regenerative Medicine (ASRM) and the Pharmaceutical and Medical Devices Act (PMDA) supports cell-derived therapeutics, and Capricor's commercialization agreement with Nippon Shinyaku Co., Ltd. positions deramiocel for Japanese regulatory submission. The Middle East and Africa, and Latin America together represent approximately 8.2% of market revenue, primarily through early-stage research activity and medical tourism for experimental exosome treatments in jurisdictions with less restrictive clinical access frameworks.
Country Analysis
The United States exosome therapeutics market reached approximately USD 593 million in 2025, growing at a country-level CAGR of approximately 10.0% through 2034. The regulatory pathway through FDA CBER's Office of Tissues and Advanced Therapies (OTAT) governs exosome biologics under PHS Act Section 351, classifying them as biologics requiring BLA approval. The FDA demonstrated pragmatic engagement with the sector by accepting and granting Priority Review to Capricor's BLA for deramiocel in March 2025, granting IND clearance to Aruna Bio in January 2024, and previously granting multiple IND approvals to Direct Biologics for ExoFlo's COVID-19 and ARDS indications. The NIH through its National Cancer Institute (NCI), National Institute of Neurological Disorders and Stroke (NINDS), and National Institute of General Medical Sciences (NIGMS) has funded extracellular vesicle research programs totaling hundreds of millions of dollars over the past decade, generating the academic pipeline from which commercial spinouts emerge. A January 2025 grant of USD 21.8 million to scientists at UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research for exosome-related work illustrates the continued federal investment in the underlying science.
South Korea's exosome therapeutics market was valued at approximately USD 58 million in 2025, growing at an estimated 14.2% CAGR—the highest single-country growth rate in the sector—anchored by the country's concentration of technically advanced exosome engineering companies. ILIAS Biologics has completed Phase 1 clinical trials of ILB-202 (engineered exosome carrying super-repressor IκB for sepsis and inflammatory conditions) with no dose-limiting toxicities or serious adverse events reported, providing the first Phase 1 safety data for an engineered intracellular protein-delivering exosome. ExoCoBio has accumulated over USD 56 million in total funding since its founding in 2017 and is advancing exosome-based atopic dermatitis and aesthetic medicine programs. South Korea's regulatory framework under the Ministry of Food and Drug Safety (MFDS) has supported these companies through designated advanced biotherapy product pathways that accelerate clinical authorization timelines. Belgium's exosome therapeutics market reached approximately USD 42 million in 2025, growing at an estimated 12.8% CAGR, powered by EXO Biologics and its ExoXpert CDMO subsidiary, which together serve both therapeutic development and contract manufacturing functions within a single organizational structure.
The United Kingdom's exosome therapeutics market was valued at approximately USD 44 million in 2025, growing at an estimated 11.5% CAGR through 2034, with Evox Therapeutics as the country's cornerstone commercial participant. Evox's Oxford location provides proximity to the University of Oxford's Jenner Institute and its network of clinical trial centers, while the company's wholly-owned ALS program—which uses DeliverEX-engineered exosomes to deliver oligonucleotide therapeutics—targets an indication where the UK's Motor Neurone Disease Association (MNDA) provides significant patient advocacy support and co-investment in research programs. The Medicines and Healthcare products Regulatory Agency (MHRA) has established a post-Brexit ATMP approval pathway that, while diverging procedurally from the EMA's route, maintains equivalent scientific standards and enables UK market authorization independent of European approvals. Portugal's Exogenus Therapeutics, while small in revenue terms, contributes to the Portuguese-Brazilian scientific corridor that is generating increasing exosome research output from institutions including the University of Coimbra.
Exosome Therapeutics Market
Size, by Region, 2025-2034 (USD)
The Market will Grow
At the CAGR of:
10.3%
The Forecast Market
Size for 2034 in USD:
$USD 3.36 B
Get more details on this report -
Key Market Segment
By Therapeutic Application
- Oncology
- Neurology
- Cardiovascular Diseases
- Regenerative Medicine
- Others
By Exosome Source
- Mesenchymal Stem Cell (MSC)-Derived Exosomes
- Immune Cell-Derived Exosomes
- Dendritic Cell-Derived Exosomes
- Others
By Technology
- Exosome Isolation & Purification
- Exosome Engineering
- Drug Delivery Technologies
- Others
By Regional Coverage
- North America
- Latin America
- East Asia And Pacific
- Sea And South Asia
- Eastern Europe
- Western Europe
- Middle East & Africa
| Report Attribute | Details |
| Market size (2025) | USD 1.39 B |
| Forecast Revenue (2034) | USD 3.36 B |
| CAGR (2025-2034) | 10.3% |
| Historical data | 2021-2025 |
| Base Year For Estimation | 2025 |
| Forecast Period | 2026-2034 |
| Report coverage | Revenue Forecast, Competitive Landscape, Market Dynamics, Growth Factors, Trends and Recent Developments |
| Segments covered | By Therapeutic Application, (Oncology, Neurology, Cardiovascular Diseases, Regenerative Medicine, Others), By Exosome Source, (Mesenchymal Stem Cell (MSC)-Derived Exosomes, Immune Cell-Derived Exosomes, Dendritic Cell-Derived Exosomes, Others), By Technology, (Exosome Isolation & Purification, Exosome Engineering, Drug Delivery Technologies, Others), |
| Research Methodology |
|
| Regional scope |
|
| Competitive Landscape | CAPRICOR THERAPEUTICS, INC., RION, INC., EVOX THERAPEUTICS LTD., EXO BIOLOGICS SA, ARUNA BIO, INC., EXOGENUS THERAPEUTICS, DIRECT BIOLOGICS, LLC, AEGLE THERAPEUTICS CORP., COYA THERAPEUTICS, INC., ILIAS BIOLOGICS INC., EXOCOBIO INC., RENEURON GROUP PLC, CARMINE THERAPEUTICS, NUREXONE BIOLOGIC INC., KIMERA LABS, ORGANICELL REGENERATIVE MEDICINE, CODIAK BIOSCIENCES (ASSETS ACQUIRED BY EVOX THERAPEUTICS), OTHERS |
| Customization Scope | Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF). |
Frequently Asked Questions
How big is the Exosome Therapeutics Market?
Global Exosome Therapeutics Market was valued at USD 1.26 billion in 2024 and is projected to reach USD 3.36 billion by 2034, at a CAGR of 10.3% (2026–2034).
Who are the major players in the Exosome Therapeutics Market?
CAPRICOR THERAPEUTICS, INC., RION, INC., EVOX THERAPEUTICS LTD., EXO BIOLOGICS SA, ARUNA BIO, INC., EXOGENUS THERAPEUTICS, DIRECT BIOLOGICS, LLC, AEGLE THERAPEUTICS CORP., COYA THERAPEUTICS, INC., ILIAS BIOLOGICS INC., EXOCOBIO INC., RENEURON GROUP PLC, CARMINE THERAPEUTICS, NUREXONE BIOLOGIC INC., KIMERA LABS, ORGANICELL REGENERATIVE MEDICINE, CODIAK BIOSCIENCES (ASSETS ACQUIRED BY EVOX THERAPEUTICS), OTHERS
Which segments covered the Exosome Therapeutics Market?
By Therapeutic Application, (Oncology, Neurology, Cardiovascular Diseases, Regenerative Medicine, Others), By Exosome Source, (Mesenchymal Stem Cell (MSC)-Derived Exosomes, Immune Cell-Derived Exosomes, Dendritic Cell-Derived Exosomes, Others), By Technology, (Exosome Isolation & Purification, Exosome Engineering, Drug Delivery Technologies, Others),
How can this market research report help my business make strategic decisions?
Our market research reports provide actionable intelligence, including verified market size data, CAGR projections, competitive benchmarking, and segment-level opportunity analysis. These insights support strategic planning, investment decisions, product development, and market entry strategies for enterprises and startups alike.
How frequently is the data updated?
We continuously monitor industry developments and update our reports to reflect regulatory changes, technological advancements, and macroeconomic shifts. Updated editions ensure you receive the latest market intelligence.
Select Licence Type
Connect with our sales team
Why IntelEvoResearch
100%
Customer
Satisfaction
24x7+
Availability - we are always
there when you need us
200+
Fortune 50 Companies trust
IntelEvoResearch
80%
of our reports are exclusive
and first in the industry
100%
more data
and analysis
1000+
reports published
till date